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Abstract When faced with an unusual clinical feature in a
patient with a Mendelian disorder, the clinician may
entertain the possibilities of either the feature representing
a novel manifestation of that disorder or the co-existence of
a different inherited condition. Here we describe an indi-
vidual with a submandibular oncocytoma, pulmonary bul-
lae and renal cysts as well as multiple cerebral cavernous
malformations and haemangiomas. Genetic investigations
revealed constitutional mutations in FLCN, associated with
Birt–Hogg–Dube´ syndrome (BHD) and CCM2, associated
with familial cerebral cavernous malformation. Intracranial
vascular pathologies (but not cerebral cavernous malfor-
mation) have recently been described in a number of
individuals with BHD (Kapoor et al. in Fam Cancer
14:595–597, 10.1007/s10689-015-9807-y, 2015) but it is
not yet clear whether they represent a genuine part of that
conditions’ phenotypic spectrum. We suggest that in such
instances of potentially novel clinical features, more
extensive genetic testing to consider co-existing conditions
should be considered where available. The increased use of
next generation sequencing applications in diagnostic set-
tings is likely to lead more cases such as this being
revealed.
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Introduction
Birt–Hogg–Dube´ syndrome (BHD) is a rare autosomal
dominant inherited neoplasia syndrome. As with most such
disorders, it is characterized by variable expression and
incomplete penetrance. First described in 1977 in a family
with facial fibrofolliculomas (the most prevalent manifes-
tation of the disease) it was subsequently recognized that
affected individuals also have an increased risk of pul-
monary cysts, spontaneous pneumothoraces and renal
tumours, particularly oncocytoma and chromophobe renal
cell carcinoma. A variety of other features have been
described including thyroid nodules and salivary gland
oncocytoma [2].
Genes associated with inherited cancer syndromes are
often discovered through the study of individuals affected
with a particular tumour type. However, the range of
tumours associated with mutations in a particular gene may
expand as more cases are uncovered through research or
clinical testing. Recently it has been proposed that
intracranial vascular pathologies may also form part of this
condition following the report of three BHD patients with a
saccular aneurysm, an arteriovenous malformation and a
carotid artery aneurysm [1].
BHD is caused by constitutional mutations in FLCN, a
tumour suppressor gene that encodes the protein folliculin.
The exact function of this protein is still under evaluation
but currently it is known to be involved in the regulation of
the mTOR pathway [3]. One consequence of upregulation
of the mTOR pathway is increased HIF1-a activity [4],
which has been observed in a patient derived renal tumour
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cell line null for FLCN gene product [5]. It has therefore
been proposed (given the role of HIF1-a in angiogenesis)
as a mechanism leading to an elevated risk of intracranial
vascular pathology in patients harbouring FLCN mutations
[1].
The definition of a rare disease is a frequency of less
than 1 in 2000 [6] but there is an appreciable probability of
a person harbouring two diseases caused by separate
genetic aberrations by chance. In theory, these individuals
are more likely (relative to those with only one condition)
to be referred for genetic counselling because of a striking
medical history but a number phenotypic consequences
arising from this situation are possible.
The clinician presented with a patient who shows fea-
tures of more than one inherited syndrome could entertain a
number of possibilities. These include a single condition
with other features in the patient due to non-genetic causes,
a new clinical feature of a recognised condition or indeed,
two genetic conditions.
Here we present a case of BHD syndrome and hereditary
cerebral cavernous malformations due to the combination
of pathogenic variants in both FLCN and CCM2 in the
same individual. The case highlights that intracranial vas-
cular pathologies may be a manifestation of concurrent
mutations in other genes rather than being caused by FLCN
mutations alone.
Case report
A 58-year-old woman was referred to clinical genetics
following the diagnosis of a variety of disease manifesta-
tions. A mandibular swelling had recently been detected,
biopsy of which showed an oncocytoma in the sub-
mandibular gland. She had previously consulted the neu-
rosurgical team due to the presence of multiple
hemangiomas/cavernous malformations in the cerebrum
and cerebellum, first diagnosed at the age of 48 years
(Fig. 1). Interrogation of her medical history revealed that
she had been diagnosed with pulmonary bullae at the age of
35 years following a spontaneous pneumothorax in the
weeks after the birth of her fourth child. At 48 years she
had also developed a goitre and facial rash.
From the medical history and clinical appearance, two
rare diseases were considered; BHD and hereditary cav-
ernous cerebral malformations (CCM). Genetic investiga-
tions of the relevant genes using a single candidate gene
testing strategy (FLCN, KRIT1, CCM2 and PDCD10)
revealed the two heterozygous frameshift mutations (FLCN
c.158del, p.Gln53 fs and CCM2 c.319C[T, p.Gln107*).
Follow-up scan of the kidneys revealed multiple small
cysts and pulmonary bullae (Fig. 2).
The family history was only partially complete as the
patient had been adopted as an infant. There was therefore
no knowledge of the paternal side of the family. Her
mother died of unknown reasons at 59 years old and she
had a half-brother on that side of the family who was
diagnosed with an intra-cerebral haematoma at age
26 years. That individual was identified by genetic testing
as harbouring the familial CCM2 mutation but not the
FLCN mutation. All of her four children are reported to be
healthy, although the third child was observed to have a
facial rash similar to that of the proband.
Discussion
Cerebral cavernous malformations consist of immature
dilated capillaries without intervening brain tissue. They
occur in both a sporadic and familial context with three
genes (KRIT1, CCM2 and PDCD10) currently implicated
in the causation of the latter. Familial CCM is inherited in
an autosomal dominant manner and typically presents in
early to mid-adulthood, often with multiple lesions that
may cause headaches, neurological deficits, seizures and
cerebral haemorrhages [7].
CCMs have an appreciable prevalence in the general
population at around 1/200 [8] so may well occur by
chance in patients with genetic conditions. However, the
presence of multiple CCMs and a truncating CCM2
mutation in this individual provides compelling evidence
that the genetic variant is the cause. Although there is a
possible mechanistic link between FLCN mutations and
vascular lesions via HIF1-a dysregulation and intracranial
vascular pathologies have been reported in BHD patients,
no CCMs were reported in that series suggesting BHD is
unlikely to be causative in this patient.
The co-occurrence of FLCN and CCM2 mutations
appears improbable given that both associated conditions
are considered rare with only a small number of families
being described. However, prevalence of genetic condi-
tions may be underestimated due to incomplete penetrance
and low rates of testing of the relevant gene by clinical
services. The increasing use of massively parallel
sequencing in clinical practice in the form of gene panels
and exome sequencing should go some way to address
these issues and produce a more accurate prevalence esti-
mate. Ultimately, mutations combinations such as this may
start to appear less improbable as a result.
Once the presence of multiple pathogenic mutations has
been detected in an individual, a pertinent question is the
likely phenotypic effect of that combination compared to if
either was present in isolation. In this case the patient pre-
sented with a phenotype consistent with the concurrent dis-
eases acting independently. However, it is feasible that
multiple mutations may act synergistically to produce more
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severe or novel phenotypes or even attenuate severity
through mechanisms such as synthetic lethality. Again,
increased detection of cases through application of next
generation sequencing technologies (and sharing in public
databases) should lead to better assessments of the likely
effects of particular combinations. Intriguingly, in the
genetics department where this patient consulted, 12 families
with BHD syndrome are known to the clinical team. Of these,
three contain at least one individual with another rare
inherited condition. This may reflect an underestimate of the
rarity ofFLCNmutations or perhaps even a higher biological
tolerance for multiple mutations involving this gene than
others.
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